Antipathy from figures close to Trump toward mRNA technology, which underlies Moderna’s products and pipeline, has weighed on ...

The average short interest in the S&P 500 Health Care Index Sector (NYSEARCA:XLV) dipped slightly in July to 1.95% from 1.96% ...

The layoffs are part of an ongoing effort to reduce operating costs amid government and competitive challenges to its vaccine business.

Perhaps the most critical aspect of Moderna's business to pay attention to right now is its late-stage pipeline. The company ...

Moderna said on Thursday it would trim roughly 10% of its global workforce and have fewer than 5,000 employees by the end of ...

The U.S. Food and Drug Administration has granted full approval for Moderna's MRNA.O COVID-19 vaccine, Spikevax, in children aged 6 months through 11 years who are at an increased risk of the ...

Reports second quarter revenues of $0.1 billion, GAAP net loss of $(0.8) billion and GAAP EPS of $(2.13) Updates 2025 ...

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss ...

Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

Moderna trimmed its 2025 revenue forecast on Friday after UK deliveries of some COVID vaccines were deferred to next year, ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough programs on its hands.

Moderna’s second-quarter sales fell less sharply than Wall Street expected as it works to expand its offerings amid weakening demand for its Covid-19 vaccine.